Neurofibromatosis Type 1 (NF1) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Neurofibromatosis Type 1 Emerging Therapy and TPP Insights

Thelansis’s “Neurofibromatosis Type 1 (NF1) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Neurofibromatosis Type 1 Overview

Neurofibromatosis type 1 (NF1) is an autosomal dominant, multisystem disorder caused by NF1 variants that reduce neurofibromin activity and dysregulate RAS–MAPK signalling. Its variable, lifelong features include café-au-lait macules, skinfold freckling, cutaneous and plexiform neurofibromas, optic pathway gliomas, skeletal abnormalities and learning difficulties. Plexiform neurofibromas can cause pain, disfigurement and neurological impairment; some may transform into malignant peripheral nerve sheath tumours. Care includes surveillance, symptom management and surgery when feasible, although complete removal may be unsafe near vital structures. MEK inhibitors have advanced treatment: selumetinib and mirdametinib are US-approved for selected patients with symptomatic, inoperable NF1-associated plexiform neurofibromas. Research is evaluating pathway-directed agents and treatments for other NF1 complications, while durability, safety and broader disease control remain unmet needs.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)